Oncolytic virus-based immunotherapies for hepatocellular carcinoma
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- MEDIATORS OF INFLAMMATION2017 · 2017
- 피인용
- Web of Science 40Scopus 44
- FWCI (Scopus)
- 0.42
- JCR IF
- JCR 2016 3.232
- ISSN
- 0962-9351
저자
- 유소영제1저자교신저자BIO-IT Foundry Technology Institute, Pusan National University, Busan, South Korea
- 바드리나트 나라아나사미BIO-IT Foundry Technology Institute, Pusan National University, Busan, South Korea
- 우현영Department of Internal Medicine, College of Medicine, Pusan National University, Medical Research Institute, Yangsan, South Korea
- 허정Department of Internal Medicine, College of Medicine, Pusan National University, Medical Research Institute, Yangsan, South Korea
초록
Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.
식별자
- Scopus EID
- 2-s2.0-85018993312
- WoS UID
- 000399497700001



로그인
연구물 목록으로